Equis ISSN 2398-2977

Cyclosporine

Synonym(s): Ciclosporin, cyclosporine, cyclosporin A, CsA

Contributor(s): Sally Anne Argyle, Brian Patterson

Introduction

Name

  • Ciclosporin (INN/BAN), formerly cyclosporin.
  • Cyclosporine (USAN).

Class of drug

  • Immunosuppressant.

Description

Chemical name

  • (E)-14,17,26,32-tetrabutyl-5-ethyl-8-(1-hydroxy-2-methylhex-4-enyl) -1,3,9,12,15,18,20,23,27-nonamethyl-11,29-dipropyl-1,3,6,9,12,15,18,21,24,27,30- undecaazacyclodotriacontan-2,4,7,10,13,16,19,22,25,28,31-undecaone.

Molecular formula

  • C62 H111 N11 O12 .

Molecular weight

  • 1202.61.

Physical properties

  • Poor solubility in water.
  • Translucent colorless to light yellow ointment.

Storage requirements

  • Optimmune® datasheet states, shelf-life of 1 month after first opening.
  • Do not store >25°C.
  • Do not freeze.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • The use of cyclosporine in equine ophthalmology is 'off label' and as such a clinician's decision to use this medication should comply with the Cascade   Therapeutics: eye  .
  • Equine recurrent uveitis   Uveitis: recurrent   (when used as a suprachoroidal medical implant, not as a topical preparation.
  • Topical preparations are used for the treatment of immune-mediated keratopathies and keratouveitis.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromPubMed.
  • Gilger B C, Wilkie D A, Clode A B, McMullen R J Jr, Utter M E, Komaromy A M, Brooks D E & Salmon J H (2010)Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis.Vet Ophthal13(5), 294-300PubMed.
  • Gilger B C, Michau T M & Salmon J H (2005)Immune-mediated keratitis in horses: 19 cases (1998-2004).Vet Ophthal8(4), 233-239PubMed.
  • Gratzek A T, Kaswan R L, Martin C L, Champagne E S & White S L (1995)Ophthalmic cyclosporine in equine keratitis and keratouveitis: 11 cases.Equine Vet J27(5), 327-333PubMed.

Other sources of information

  • Matthews A (2004)Ophthalmic Therapeutics. In:Equine Clinical Pharmacology. Eds: Bertone J & Horspool L. pp 217-246.
  • Report a Suspect Adverse Reaction.Veterinary Medicines Directorate. Website:www.vmd.defra.gov.uk/adversereactionreporting.

ADDED